Paclitaxel mediates the PI3K/AKT/mTOR pathway to reduce proliferation of FLT3‑ITD+ AML cells and promote apoptosis
- Authors:
- Yanyun Su
- Meiqing Wu
- Baowen Zhou
- Ziwen Bai
- Ruli Pang
- Zhenfang Liu
- Weihua Zhao
-
Affiliations: Department of Hematology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China - Published online on: February 23, 2024 https://doi.org/10.3892/etm.2024.12449
- Article Number: 161
-
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Estey E and Döhner H: Acute myeloid leukaemia. Lancet. 368:1894–1907. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Yang F, Anekpuritanang T and Press RD: Clinical utility of next-generation sequencing in acute myeloid leukemia. Mol Diagn Ther. 24:1–13. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 368:2059–2074. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Daver N, Schlenk RF, Russell NH and Levis MJ: Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia. 33:299–312. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sun YM, Wang WT, Zeng ZC, Chen TQ, Han C, Pan Q, Huang W, Fang K, Sun LY, Zhou YF, et al: CircMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. Blood. 134:1533–1546. 2019.PubMed/NCBI View Article : Google Scholar | |
|
De Kouchkovsky I and Abdul-Hay M: ‘Acute myeloid leukemia: A comprehensive review and 2016 update’. Blood Cancer J. 6(e441)2016.PubMed/NCBI View Article : Google Scholar | |
|
Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 111:1552–1559. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group b study. Cancer Res. 61:7233–7239. 2001.PubMed/NCBI | |
|
Almatani MF, Ali A, Onyemaechi S, Zhao Y, Gutierrez L, Vaikari VP and Alachkar H: Strategies targeting FLT3 beyond the kinase inhibitors. Pharmacol Ther. 225(107844)2021.PubMed/NCBI View Article : Google Scholar | |
|
Levis M and Small D: FLT3: It does matter in leukemia. Leukemia. 17:1738–1752. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Takahashi S: Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: Biology and therapeutic implications. J Hematol Oncol. 4(13)2011.PubMed/NCBI View Article : Google Scholar | |
|
Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, et al: Constitutive activation of Akt by FLT3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 65:9643–9650. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP and Gilliland DG: Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 108:1339–1345. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, et al: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 485:260–263. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Piloto O, Levis M, Huso D, Li Y, Li H, Wang MN, Bassi R, Balderes P, Ludwig DL, Witte L, et al: Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 65:1514–1522. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M and Cortes JE: Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 120:2142–2149. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Weisberg E, Barrett R, Liu Q, Stone R, Gray N and Griffin JD: FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 12:81–89. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, et al: Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2:125–134. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhu L and Chen L: Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 24(40)2019.PubMed/NCBI View Article : Google Scholar | |
|
Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A and Argyriou AA: Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 24 (Suppl 2):S40–S51. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Leung JC and Cassimeris L: Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: Roles of depolymerizing kinesins and severing proteins. Cancer Biol Ther. 20:1337–1347. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Vassileva V, Allen CJ and Piquette-Miller M: Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 7:630–637. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Al-Mahayri ZN, AlAhmad MM and Ali BR: Current opinion on the pharmacogenomics of paclitaxel-induced toxicity. Expert Opin Drug Metab Toxicol. 17:785–801. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li T: Pacilitaxel induces human nasopharyngeal carcinoma cell line CNE2 apoptosis and growth inhibition by suppressing PI3K/AKT/P53 signaling pathway. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 29:2147–2150. 2015.PubMed/NCBI(In Chinese). | |
|
Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ma D, Li S, Cui Y, Li L, Liu H, Chen Y and Zhou X: Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/AKT pathway. Oncol Lett. 15:6211–6216. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, et al: Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 72:1814–1824. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ying J, Yang W, Xie CY, Ni QC, Pan XD, Dong JH, Liu ZM and Wang XS: Induction of caspase-3-dependent apoptosis in human leukemia HL-60 cells by δ-elemene. Yakugaku Zasshi. 131:1383–1394. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Xia RL, Lu Y, Zhu LN, Zhang SF, Zhao FK and Fu CY: Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel. Oncol Rep. 30:1853–1859. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Meshkini A and Yazdanparast R: Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol. 64:357–365. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Bai ZW, Wu MQ, Zhou BW, Shi ZY, Yao YB, Liu ZF, Pang RL and Zhao WH: Effects of paclitaxel and quizartinib alone and in combination on aml cell line MV4-11 and Its STAT5 signal pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 30:671–676. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Jin ZJ and Zhang XW: Equal probability and curve with ‘q50’-A new method to estimate the effect of drug combination. Journal of Shanghai Second Medical College. (01)(15-18+86)1981.(In Chinese). | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Nepstad I, Hatfield KJ, Grønningsæter IS and Reikvam H: The PI3K-AKT-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 21(2907)2020.PubMed/NCBI View Article : Google Scholar | |
|
Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, et al: Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 25:1064–1079. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, et al: Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. 35:5119–5131. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A and Pouryamout L: Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and cebpa gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: A systematic review and meta-analysis. Ann Hematol. 93:1279–1286. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Almond LM, Charalampakis M, Ford SJ, Gourevitch D and Desai A: Myeloid sarcoma: Presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 17:263–267. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ganzel C and Douer D: Extramedullary disease in APL: A real phenomenon to contend with or not? Best Pract Res Clin Haematol. 27:63–68. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Levis M: Midostaurin approved for FLT3-mutated AML. Blood. 129:3403–3406. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, Przepiorka D, Fu W, Okusanya OO, Goldberg KB, et al: FDA approval summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clin Cancer Res. 27:3515–3521. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Antar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M and Bazarbachi A: Inhibition of FLT3 in AML: A focus on sorafenib. Bone Marrow Transplant. 52:344–351. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cucchi DGJ, Denys B, Kaspers GJL, Janssen J, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, et al: RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. Blood. 131:2485–2489. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Mrózek K, Marcucci G, Paschka P, Whitman SP and Bloomfield CD: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood. 109:431–448. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS and Ko YW: Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia. 17:995–997. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ and Rassidakis HZ: Mtor signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer. 9(292)2010.PubMed/NCBI View Article : Google Scholar | |
|
Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, Rye KP, Berven FS, Selheim F, Reikvam H and Bruserud Ø: Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct Target Ther. 4(20)2019.PubMed/NCBI View Article : Google Scholar | |
|
Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y and Miura O: FLT3-ITD activates RSK1 to enhance proliferation and survival of AML cells by activating mTORC1 and eIF4B cooperatively with PIM or PI3K and by inhibiting BAD and BIM. Cancers (Basel). 11(1827)2019.PubMed/NCBI View Article : Google Scholar | |
|
Dong P, Hao F, Dai S and Tian L: Combination therapy eve and pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways. J Recept Signal Transduct Res. 38:83–88. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ding Z, Xu F, Li G, Tang J, Tang Z, Jiang P and Wu H: Knockdown of Akt2 expression by shRNA inhibits proliferation, enhances apoptosis, and increases chemosensitivity to paclitaxel in human colorectal cancer cells. Cell Biochem Biophys. 71:383–388. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL and Hsu LC: The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 388:19–31. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou S, Shen J, Huo Z, Cao W, Ma Y, et al: BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. Am J Transl Res. 11:7255–7271. 2019.PubMed/NCBI | |
|
Hacıhanefioglu A, Gonullu E, Mehtap O, Keski H, Yavuz M and Ercin C: Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: An immunohistochemical study. Med Oncol. 28:846–851. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Han SY: Small molecule induced FLT3 degradation. Pharmaceuticals (Basel). 15(320)2022.PubMed/NCBI View Article : Google Scholar | |
|
Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA and Kersey JH: FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res. 9:4483–4493. 2003.PubMed/NCBI | |
|
Ly BT, Chi HT, Yamagishi M, Kano Y, Hara Y, Nakano K, Sato Y and Watanabe T: Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One. 8(e66378)2013.PubMed/NCBI View Article : Google Scholar | |
|
Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A and Rowntree C: Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol. 141:483–493. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al: Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 10:321–330. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Peng B, Xu L, Cao F, Wei T, Yang C, Uzan G and Zhang D: HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer. 9(79)2010.PubMed/NCBI View Article : Google Scholar | |
|
Lu Z, Jin Y, Qiu L, Lai Y and Pan J: Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 290:182–191. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zhang FZ, Ho DH and Wong RH: Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner. Oncotarget. 9:22301–22315. 2018.PubMed/NCBI View Article : Google Scholar |
